GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease
Identifieur interne : 000061 ( Main/Exploration ); précédent : 000060; suivant : 000062GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease
Auteurs : Chong Gao [République populaire de Chine] ; Christian Hölscher [Royaume-Uni] ; Yueze Liu [République populaire de Chine] ; Lin Li [République populaire de Chine]Source :
- Reviews in the Neurosciences [ 0334-1763 ] ; 2012-02-01.
Abstract
As a constitutively active kinase, glycogen synthase kinase 3 (GSK3) is a kinase which regulates body metabolism by phosphorylation of glycogen synthase (GS) and other substrates. Considerable evidence suggests that GSK3 is involved in the common pathology underlying Alzheimer’s disease (AD) and type 2 diabetes mellitus (T2DM). The overexpression or overactivation of GSK3 could induce a series of pathological changes, most of which are hallmarks of AD and T2DM. Therefore, GSK3 could be a novel target to treat these two age-dependent diseases. The inhibition of this kinase can prevent the aggregation of β-amyloid (Aβ) and hyperphosphorylation of tau protein. GSK3 inhibition can also be a promising strategy to ameliorate neurodegenerative developments. Its potential association with memory formation has been shown in electrophysiological and behavioral experiments. The neuroprotective effects of novel drugs developed to treat T2DM, glucagon-like peptide 1 (GLP-1) and its long-lasting analogs, have a possible link to GSK3 modification. Recent investigations of the interaction between the phosphatidylinositol 3 kinase (PI3K) signaling pathway and the protective effect of novel GPL-1 receptor agonist geniposide on PC12 cells support this theory.
Url:
DOI: 10.1515/rns.2011.061
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease</title><author><name sortKey="Gao, Chong" sort="Gao, Chong" uniqKey="Gao C" first="Chong" last="Gao">Chong Gao</name></author><author><name sortKey="Holscher, Christian" sort="Holscher, Christian" uniqKey="Holscher C" first="Christian" last="Hölscher">Christian Hölscher</name></author><author><name sortKey="Liu, Yueze" sort="Liu, Yueze" uniqKey="Liu Y" first="Yueze" last="Liu">Yueze Liu</name></author><author><name sortKey="Li, Lin" sort="Li, Lin" uniqKey="Li L" first="Lin" last="Li">Lin Li</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:42B2B54B46BC722D15DD9A320B25B12251AD24DC</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1515/rns.2011.061</idno><idno type="url">https://api.istex.fr/document/42B2B54B46BC722D15DD9A320B25B12251AD24DC/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002483</idno><idno type="wicri:Area/Main/Curation">002154</idno><idno type="wicri:Area/Main/Exploration">000061</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease</title><author><name sortKey="Gao, Chong" sort="Gao, Chong" uniqKey="Gao C" first="Chong" last="Gao">Chong Gao</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Physiology, Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, 030001</wicri:regionArea><wicri:noRegion>030001</wicri:noRegion></affiliation></author><author><name sortKey="Holscher, Christian" sort="Holscher, Christian" uniqKey="Holscher C" first="Christian" last="Hölscher">Christian Hölscher</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>School of Biomedical Sciences, University of Ulster, Coleraine, BT52 1SA</wicri:regionArea><wicri:noRegion>BT52 1SA</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Yueze" sort="Liu, Yueze" uniqKey="Liu Y" first="Yueze" last="Liu">Yueze Liu</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Physiology, Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, 030001</wicri:regionArea><wicri:noRegion>030001</wicri:noRegion></affiliation></author><author><name sortKey="Li, Lin" sort="Li, Lin" uniqKey="Li L" first="Lin" last="Li">Lin Li</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Physiology, Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, 030001</wicri:regionArea><wicri:noRegion>030001</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Reviews in the Neurosciences</title><title level="j" type="abbrev">Reviews in the Neurosciences</title><idno type="ISSN">0334-1763</idno><idno type="eISSN">2191-0200</idno><imprint><publisher>Walter de Gruyter</publisher><date type="published" when="2012-02-01">2012-02-01</date><biblScope unit="volume">23</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="1">1</biblScope><biblScope unit="page" to="11">11</biblScope></imprint><idno type="ISSN">0334-1763</idno></series><idno type="istex">42B2B54B46BC722D15DD9A320B25B12251AD24DC</idno><idno type="DOI">10.1515/rns.2011.061</idno><idno type="ArticleID">rns.2011.061</idno><idno type="Related-article-Href">rns.2011.061.pdf</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0334-1763</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">As a constitutively active kinase, glycogen synthase kinase 3 (GSK3) is a kinase which regulates body metabolism by phosphorylation of glycogen synthase (GS) and other substrates. Considerable evidence suggests that GSK3 is involved in the common pathology underlying Alzheimer’s disease (AD) and type 2 diabetes mellitus (T2DM). The overexpression or overactivation of GSK3 could induce a series of pathological changes, most of which are hallmarks of AD and T2DM. Therefore, GSK3 could be a novel target to treat these two age-dependent diseases. The inhibition of this kinase can prevent the aggregation of β-amyloid (Aβ) and hyperphosphorylation of tau protein. GSK3 inhibition can also be a promising strategy to ameliorate neurodegenerative developments. Its potential association with memory formation has been shown in electrophysiological and behavioral experiments. The neuroprotective effects of novel drugs developed to treat T2DM, glucagon-like peptide 1 (GLP-1) and its long-lasting analogs, have a possible link to GSK3 modification. Recent investigations of the interaction between the phosphatidylinositol 3 kinase (PI3K) signaling pathway and the protective effect of novel GPL-1 receptor agonist geniposide on PC12 cells support this theory.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li><li>République populaire de Chine</li></country></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Gao, Chong" sort="Gao, Chong" uniqKey="Gao C" first="Chong" last="Gao">Chong Gao</name></noRegion><name sortKey="Li, Lin" sort="Li, Lin" uniqKey="Li L" first="Lin" last="Li">Lin Li</name><name sortKey="Liu, Yueze" sort="Liu, Yueze" uniqKey="Liu Y" first="Yueze" last="Liu">Yueze Liu</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Holscher, Christian" sort="Holscher, Christian" uniqKey="Holscher C" first="Christian" last="Hölscher">Christian Hölscher</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000061 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000061 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:42B2B54B46BC722D15DD9A320B25B12251AD24DC
|texte= GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease
}}
| This area was generated with Dilib version V0.6.23. |  |